Shaping the Future of Medicine: How Tiny Devices Are Revolutionising Vital Body Functions

By Henry Duah

Imagine a world where complex health conditions are monitored and treated not by bulky machines or invasive surgeries, but through tiny, sophisticated devices seamlessly integrated within the human body. This is not science fiction; it’s the cutting edge of medical innovation happening today.

As chronic diseases rise globally and populations age, the demand for more innovative, less invasive, and more connected medical devices has led to transformative breakthroughs that can restore independence and improve quality of life. This innovation snapshot highlights the remarkable work of three pioneering companies in the medical devices innovation space—InVivo Bionics, Bivacor, and Synchron.

These companies have targeted some of the body’s most critical systems: the bladder, heart, and brain. Through breakthroughs in microsensor technology, implantable heart pumps, and minimally invasive neurointerfaces, these companies are rewriting the playbook for healthcare. By embracing miniaturisation, wireless connectivity, and advanced neurotechnology, they are empowering patients and clinicians with real-time data, personalised treatment and new therapeutic possibilities. Overall, these trends highlight a broader movement shifting healthcare from periodical, hospital-bound interventions to continuous patient-centred care anytime, anywhere.

Innovation Spotlight

Bivacor: Innovating the Future of Heart Pump Technology
(Founded: 2008, HQ: USA)
Bivacor is developing a cutting-edge implantable heart pump designed to address the limitations of existing ventricular assist devices. Their unique technology features a fully implantable, durable, and compact blood pump that offers continuous circulatory support for patients with advanced heart failure. With a focus on improving patient mobility and quality of life, Bivacor’s device seeks to minimise the risk of infection and mechanical failures associated with external components or transcutaneous driveline systems. By enhancing longevity and reliability, this breakthrough has the potential to redefine long-term cardiac support and enable more patients to recover or undergo transplantation.

Synchron: Bridging Mind and Machine through Minimally Invasive Neurotechnology
(Founded: 2016, HQ: USA)
Synchron is at the forefront of neurotechnology with its innovative brain-computer interface (BCI) designed to restore communication and interaction abilities for individuals with paralysis or neurological disorders. Utilising a minimally invasive endovascular approach similar to stent placement, Synchron’s device implants inside the brain’s blood vessels, eliminating the need for open brain surgery. This approach enables patients to control digital devices solely through thought, opening up new frontiers in assistive technology for mobility, communication and independence. Synchron’s work embodies the convergence of neurology and engineering to unlock unprecedented therapeutic possibilities that enhance cognitive and functional recovery.

InVivo Bionics: Revolutionising Bladder Health with a Microsensor Breakthrough
(Founded: 2018, HQ: Norway)
InVivo Bionics is transforming the understanding and management of urinary dysfunction, a condition affecting nearly 900 million people worldwide, including those with benign prostatic hyperplasia, urinary incontinence and neurogenic bladder disorders. Their patented microsensor technology, currently under development —Pressuro—is a tiny (less than 1 mm) MEMS pressure sensor inserted via a minimally invasive suprapubic procedure that continuously monitors bladder pressure in real-time. The sensor wirelessly streams high-resolution data via 4G to the cloud, providing clinicians and researchers with unprecedented insights into bladder function. This all-in-one diagnostic solution offers a paradigm shift from episodic, subjective assessments to continuous, objective data, enabling personalised treatment and significantly improving patient outcomes.

Get innovation insights from The FutureList weekly. Subscribe to our newsletter here